25.2-30.2). Predictors of patient satisfaction in the PD group were absence of pain during closure, decreased TTA, and drastic reductions in TTD; the latter contributed indirectly to significant cost-savings in the PD group (1,282.3 118.3 vs. 2,271.4 121.1 dollars, respectively; P<0.001) and incremental cost savings by strategy also favored closure over MC ($89,124.5). CONCLUSIONS ProGlide is safe and effective for femoral artery closure in patients who ambulate within 30 min after cardiac catheterization; all of which translated into improved patient satisfaction and substantial cost savings. COMPLEX CORONARY INTERVENTION CRT-146 In-Drug Eluting Stent Restenosis Treated By Paclitaxel Coated Balloon Angioplasty: Results From The French Prospective Garo Registry Marc Bedossa, 1 Vincent Auffret, 1 Paul Barragan, 2 Matthias Waliszenski, 3 Laurent Bonello, 4 Nicolas Delarche, 5 Alain Furber, 6 Franck Albert, 7 Didier Carrié, 8 Jacques Berland 9 1 Dpt of Cardiology, Rennes, France; 2 Polyclinique Les Fleurs, Ollioules, France; 3 Medical Scientific Affairs, B Braun, Melsungen AG, Germany; 4 Hopital Nord, Marseille, France; 5 Centre hospitalier, Pau, France; 6 CHU, Angers, France; 7 CHG, Chartres, France; 8 CHU, Toulouse, France; 9 Clinique St Hilaire, Rouen, France BACKGROUND The clinical benefits of paxlitaxel-coated balloon angioplasty (PCB) have been extensively studied in bare metal stent in-stent restenosis (BMS-ISR) and in drug eluting stent in-stent restenosis (DES-ISR). The GARO Registry is a dedicated ‘all comers’ study in an unselected patient population with DES-ISR to elucidate the clinical benefits of PCB angioplasty for various types of DES-ISR in a routine clinical setting. METHODS Under the supervision of the GARO (Groupe Angioplastie de la Région Ouest) all data for patients treated by the PCB based on the Paccocath Ò Technology (SeQuent Ò Please, B.Braun Melsungen AG) for In DES-ISR were collected in a pro- spective data base. Quantitative analyses of the angiography of the procedure were made by an independent core lab. The primary endpoint was clinically driven TLR at 9 months while secondary endpoints consisted of the clinically driven rates of MACE, MI and cardiac death. RESULTS A total of 206 patients (67.7  10.3 y, 80.6% male gender) with 210 DES-ISR lesions were recruited in 15 French study centers. Major cardiovascular risk factors were diabetes (41.3%), hypertension (69.4%), hypercholesterolemia (75.7%) and his- tory of smoking (47.6%). STEMI (3.9%) and NSTEMI (13.1%) were present at baseline. Lesion characteristics were 3.02  0.64 mm (reference vessel diameter) and 14.6  6.5 mm (lesion length). Treated vessels were LAD (37.6%), RCA (28.6%), LCX (27.6%) and others (6.2%). Cypher-ISR (36.7%) was the most common type of DES-ISR fol- lowed by Taxus-ISR (20.0%), Xience-ISR (20.0%), Promus-ISR (8.1%), Endeavor-ISR (5.7%) and others (9.5%). ISR patterns were focal (52.9%) and diffuse (47.1%). 9-month follow-up was available in 90.8% (187/206) of all patients. The duration between DES implantation and restenosis was 3.0  2.4 years. The 9-month TLR rate was 7.0% (13/187) whereas incidences of MI and cardiac death were 4.3% (8/187) and 2.1% (4/187) respectively. The composite MACE rate at 9 months was 10.2% (19/187). CONCLUSIONS Up to date this is the largest prospective registry in an unselected patient population with DES-ISR treated with PCB angioplasty. The rates for TLR and MACE were low and seem to be an attractive alternative treatment option despite the lack of reimbursement in France. CRT-147 The Efficacy and Clinical Outcome of Rotational Atherectomy with Second Generation Drug-Eluting Stents Koshi Matsuo, Yasunori Ueda Osaka Police Hospital, Osaka, Japan BACKGROUND Treatment of calcified lesions with balloon angioplasty has been associated with a low success rate and high procedural complications. Rotational atherectomy (RA) improved acute results, but a high restenosis rate remained a problem. Therefore, the purpose of this study was to evaluate the clinical and angiographic outcome of patients with complex and calcified lesions treated with a combination of RA and second-generation drug-eluting stent (DES) implantation. METHODS Consecutive 55 patients received combination therapy of RA and second- generation DES implantation at de novo lesion of native coronary artery with severe calcification between June 2009 and December 2012. Zotarolimus-eluting stents (ZES), biolimus-eluting stent (BES), and everolimus-eluting stents (EES) were used in 14, 7, and 34 patients, respectively. 39 patients (ZES, BES, and EES were used in 12, 6, 21 patients) received one-year follow-up angiography. The clinical and angiographic outcome was compared among those 3 groups of different DES. RESULTS Only one patient was dead (a cause was unknown). Target lesion revascu- larization (TLR) rate was 0% among 3 groups. The late loss was larger in ZES than in BES or EES (ZES vs. BES vs. EES: 0.370.20mm vs. 0.200.10mm vs. 0.160.15mm, p<0.05). CONCLUSION The clinical outcome of 3 second-generation DES used in combination with RA was very good, although the culprit lesions were complex with severe calcification. Combination therapy of RA and second-generation DES appeared ac- ceptable. CRT-148 A Study Of Conformability in Everolimus-eluting Bioresorbable Vascular Scaffolds to Metal Platform Coronary Stents in Long Lesions Jiang Ming Fam, 1 Yoshinobu Onuma, 2 Yuki Ishibashi, 2 Roberto Diletti, 2 Nicolas van Mieghem, 2 Ron van Domburg, 2 Jolanda Wentzel, 2 Frank Gijsen, 2 Robert-Jan van Geuns 2 1 National Heart Centre Singapore, Singapore, Singapore; 2 Erasmus Medical Centre, Rotterdam, Netherlands INTRODUCTION Implantation of stiff permanent metallic implants alters blood rheology especially at the inflow and outflow edge of the stents probably contributing to early and late stent failure. Short Polymeric Bioresorbable vascular scaffolds (BVS) have shown to have less impact on the natural curvature of the stent vessel compared to Metal platform stents (MPS). The impact of long BVS on vessel curvature is unknown. OBJECTIVES The aim of this study was to determine if there are any significant dif- ferences in terms of curvature of the treated vessel after the deployment of either a metallic stent or a polymeric scaffold device in long lesions. METHODS This retrospective study compares 32 patients who received an MPS (Xience, Abbott Vascular, Santa Clara, CA, US) with 32 patients treated with the ever- olimus-eluting bioresorbable vascular scaffold (BVS-Absorb, Abbott Vascular, Santa Clara, California). All patients received 1 BVS Absorb or MPS with a length of 28mm deployed singly in long coronary lesions. The primary end point measured was the relative region curvature (%) evaluated with dedicated software by angiography. RESULTS There were 22 (68.8%) males in each group. There was no difference in median age [BVS vs MPS: 59.6 yrs vs 64.9 yrs, p¼0.453)]. There was a significant difference in clinical presentation of ACS/STEMI (BVS vs MPS: 68.8% vs 40.6%, p¼ 0.024). The left anterior descending artery was the most treated vessel in both groups (BVS vs MPS: 46.9% vs 40.6%, p¼ 0.857). Pretreatment length was 22.19 mm vs 20.38 mm in the BVS and MPS groups respectively (p¼0.803). There was no signifi- cant differences in reference vessel diameter, minimal lumen diameter and per- centage diameter stenosis in both groups. Pretreatment Diastolic curvature (DC) was greater in the BVS group compared with the MPS group (0.305 cm -1 vs 0.257 cm -1 ,p¼ 0.803). There was a significant decrease in median DC in the MPS group post-treat- ment than pre-treatment (from 0.257 cm -1 to 0.199 cm -1 ,p¼ 0.001). There was a decrease in median DC in the BVS group post-treatment which trends towards sig- nificance (from 0.305 cm -1 to 0.283 cm -1 ,p¼ 0.056). Median Percentage relative change in DC was significantly lower in the BVS group compared with the MPS group (BVS vs MPS: 7.48% vs 29.4%, p¼ 0.024). By univariate analysis, device use was an independent predictor of change in curvature (p ¼ 0.022). CONCLUSIONS In the deployment of long coronary scaffolds/ stents (28mm in length), bioresorbable vascular scaffolds provides better conformability compared with MPS. CRT-149 Role of Plaque Characterization By 64-slice Multi Detector Computed Tomography in Prediction of Complexity of Percutaneous Coronary Interventions Sherif W. Ayad, Mohamed A. Sobhy, Eman M. El-Sharkawy, Mahmoud S. Abd-Elhamid Faculty of Medicine, Alexandria, Egypt BACKGROUND Percutaneous coronary intervention (PCI) nowadays has become standard of care in symptomatic coronary artery disease (CAD. Lesion localization, severe calcifications, and vessel tortuosity may challenge the skills of the operator and increase the risk of procedural complications. Coronary computed tomography angiography (CCTA) has become a promising non-invasive imaging technique, pre- procedural lesion characterization by CCTA might contribute to predict PCI complexity in extensive and complex CAD. AIM To determine the predictive value of coronary plaque characterization as detected by 64- slice multi-detector Computed tomography(MDCT) in prediction of the procedural complexity of elective percutaneous coronary non CTO intervention. PATIENTS Retrospective study involving 45 patients in whom PCIs were performed for 60 single coronary lesions within 6 months of pre-procedural CCTA at ICC hospital. METHODS All patients had MDCT coronary angiography The CT derived parameters included in our study was: calcium scoring, plaque anatomy (site, side branch involvement, degree of stenosis, morphological type), plaque length, volume, density and area. RESULTS Median Agatston score was significantly higher in lesions with complex as compared to those with non-complex interventions with a mean of 266.51 155.93vs 168.76  70.53 with the P value ¼ 0.034. Regarding plaque density, Hounsfield Units were higher in lesions with complex as compared to non-complex PCI (371.85 (48.0 to S22 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 8, NO. 2, SUPPL S, 2015 CORONARY